Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease

Alzheimer's and Dementia

Volumn 3, Issue 1, 2007, Pages 21-22

  Knopman, David S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 33846125247     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.10.002     Document Type: Note

References (2)

1. DeAngelis C.D., Drazen J.M., Frizelle F.A., Haug C., Hoey J., Horton R., et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 292 (2004) 1363-1364
2. Peskind E.R., Potkin S.G., Pomara N., Ott B.R., Graham S.M., Olin J.T., et al. memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14 (2006) 704-715